<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313479421</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313479421</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of a single nucleotide polymorphism in the <italic>SH2D1A</italic> intronic region with systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Furukawa</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479421">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313479421"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kawasaki</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313479421">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oka</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479421">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shimada</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
<xref ref-type="aff" rid="aff4-0961203313479421">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Matsui</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ikenaka</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hashimoto</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Okazaki</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Takaoka</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Futami</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479421">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Komiya</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479421">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kondo</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479421">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ito</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479421">5</xref>
<xref ref-type="aff" rid="aff6-0961203313479421">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hayashi</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479421">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Matsumoto</surname><given-names>I</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479421">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kusaoi</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff7-0961203313479421">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Takasaki</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff7-0961203313479421">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nagai</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff8-0961203313479421">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hirohata</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff8-0961203313479421">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Setoguchi</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff9-0961203313479421">9</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suda</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff10-0961203313479421">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nagaoka</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff10-0961203313479421">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kono</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff11-0961203313479421">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Okamoto</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff12-0961203313479421">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chiba</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff13-0961203313479421">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suematsu</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff14-0961203313479421">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fukui</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479421">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hashimoto</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff15-0961203313479421">15</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sumida</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479421">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ono</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff16-0961203313479421">16</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsuchiya</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313479421">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tohma</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479421">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313479421"><label>1</label>Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Japan</aff>
<aff id="aff2-0961203313479421"><label>2</label>Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Japan</aff>
<aff id="aff3-0961203313479421"><label>3</label>Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Japan</aff>
<aff id="aff4-0961203313479421"><label>4</label>Tokyo Metropolitan Tama Medical Center, Japan</aff>
<aff id="aff5-0961203313479421"><label>5</label>Division of Clinical Immunology, Faculty of Medicine, University of Tsukuba, Japan</aff>
<aff id="aff6-0961203313479421"><label>6</label>Department of Rheumatology, Niigata Rheumatic Center, Japan</aff>
<aff id="aff7-0961203313479421"><label>7</label>Division of Rheumatology, Department of Internal Medicine, Juntendo University, Japan</aff>
<aff id="aff8-0961203313479421"><label>8</label>Department of Rheumatology and Infectious Disease, Kitasato University School of Medicine, Japan</aff>
<aff id="aff9-0961203313479421"><label>9</label>Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan</aff>
<aff id="aff10-0961203313479421"><label>10</label>Department of Rheumatology, Yokohama Minami Kyosai Hospital, Japan</aff>
<aff id="aff11-0961203313479421"><label>11</label>Department of Internal Medicine, Teikyo University, Japan</aff>
<aff id="aff12-0961203313479421"><label>12</label>Department of Rheumatology, Himeji Medical Center, National Hospital Organization, Japan</aff>
<aff id="aff13-0961203313479421"><label>13</label>Department of Rheumatology, Morioka Hospital, National Hospital Organization, Japan</aff>
<aff id="aff14-0961203313479421"><label>14</label>Department of Internal Medicine and Rheumatology, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization, Japan</aff>
<aff id="aff15-0961203313479421"><label>15</label>Juntendo University School of Medicine, Japan</aff>
<aff id="aff16-0961203313479421"><label>16</label>Department of Pathology, Tohoku University Graduate School of Medicine, Japan</aff>
<author-notes>
<corresp id="corresp1-0961203313479421">Hiroshi Furukawa, Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan. Email: <email>h-furukawa@sagamihara-hosp.gr.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>497</fpage>
<lpage>503</lpage>
<history>
<date date-type="received"><day>30</day><month>10</month><year>2012</year></date>
<date date-type="accepted"><day>21</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>SH2D1A, also known as signaling lymphocytic activation molecule (SLAM)-associated protein (SAP), is an adaptor protein. Recently, it was reported that SAP deficient mice were protected from systemic lupus erythematosus (SLE). In this study, we postulated <italic>SH2D1A</italic> gene to be a candidate susceptibility gene for SLE and analyzed its association with SLE. A case-control association study was conducted on 5 tag single nucleotide polymorphisms (SNPs) in <italic>SH2D1A</italic> region in 506 Japanese female SLE patients and 330 healthy female controls. The luciferase assay was performed to determine the functional role of the SNP associated with SLE. One SNP in the intron 2, rs2049995, showed association with SLE (<italic>p</italic> = 0.0110, odds ratio (OR) 1.97, 95% confidence interval (CI) 1.16–3.34, under the dominant model). The association of rs2049995 seemed to be stronger in the subset with the age of onset less than 20 years (<italic>p</italic> = 0.0067, OR 2.65, 95% CI 1.28–5.46). Functional evaluation of rs2049995 showed that reporter gene activity was increased 1.9-fold for the susceptible allele compared with the resistant allele. An intronic SNP of <italic>SH2D1A</italic> is associated with SLE.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>medical genetics</kwd>
<kwd>single nucleotide polymorphism</kwd>
<kwd>SH2D1A</kwd>
<kwd>SLAM-associated protein</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313479421" sec-type="intro"><title>Introduction</title>
<p>Signaling lymphocytic activation molecule (SLAM) family receptors belong to the immunoglobulin (Ig) superfamily, possessing either two or four Ig domains in the extracellular domain of the molecule and one or more immunoreceptor tyrosine-based switching motifs (ITSM, TI/VYXXV/I) in their cytoplasmic tails, which bind to the Src homology 2 (SH2) domain of a SLAM-associated protein (SAP, SH2D1A) molecule. SAP is an adaptor molecule containing an SH2 domain and a short C-terminal tail.<sup><xref ref-type="bibr" rid="bibr1-0961203313479421">1</xref></sup> It is expressed in T, NK and NKT cells. The binding of SAP with SLAM in T cells results in the subsequent recruitment of the Src family kinase Fyn, leading to the activation of NF-χB, resulting in IL-4 production and Th2 responses.<sup><xref ref-type="bibr" rid="bibr2-0961203313479421">2</xref></sup> The SAP gene in humans, <italic>SH2D1A</italic>, is located on the X chromosome (Xq25), and in the mouse, <italic>Sh2d1a</italic>, it is located on the mouse XA4 chromosome region.<sup><xref ref-type="bibr" rid="bibr1-0961203313479421">1</xref></sup></p>
<p>We found spontaneous mutants in the MRL/Mp-<italic>Fas<sup>lpr/lpr</sup></italic> (MRL/lpr) mice<italic>,</italic> a lupus-prone strain of mice. The long-living mutant MRL/Mp-<italic>Fas<sup>lpr/lpr</sup></italic><sup> </sup>·<sup> </sup><italic>Sap<sup>rpl/-</sup></italic> (MRL/lpr/rpl) mice displayed minimal autoimmune phenotypes.<sup><xref ref-type="bibr" rid="bibr3-0961203313479421">3</xref></sup> A positional cloning study revealed that there was a frameshift mutation in the <italic>Sh2d1a</italic> gene of the MRL/lpr/rpl mice. In addition, Fyn-deficient MRL/lpr mice lost the lupus phenotypes similar to MRL/lpr/rpl mice.<sup><xref ref-type="bibr" rid="bibr4-0961203313479421">4</xref></sup> These findings indicated that the SLAM-SAP signaling pathway is essential for the induction of lupus.</p>
<p>Genetic studies using lupus-prone mice identified a lupus susceptibility locus, <italic>Sle1b,</italic> which overlapped with the loci of SLAM family receptors. One of these SLAM family receptor genes, <italic>Ly108,</italic> was shown to cause lupus.<sup><xref ref-type="bibr" rid="bibr5-0961203313479421">5</xref></sup> A polymorphic <italic>z</italic> allele of <italic>Sle1b</italic> from the NZW strain altered the expression pattern of two splicing variants of <italic>Ly108</italic> and increased susceptibility to lupus. In genetic studies on systemic lupus erythematosus (SLE) patients, single nucleotide polymorphisms (SNPs) in the <italic>LY9</italic> gene, one of the SLAM family receptor genes, were associated with SLE susceptibility in Europeans.<sup><xref ref-type="bibr" rid="bibr6-0961203313479421">6</xref></sup> It was also reported that SNPs in <italic>2B4</italic>, one of the SLAM family receptor genes, were associated with rheumatoid arthritis (RA) and with SLE in Japanese patient cohorts.<sup><xref ref-type="bibr" rid="bibr7-0961203313479421">7</xref></sup> In addition, the expression of SAP was reduced in peripheral T cells from RA patients,<sup><xref ref-type="bibr" rid="bibr8-0961203313479421">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203313479421">9</xref></sup> whereas the expression of SLAM was increased in peripheral B cells from these patients.<sup><xref ref-type="bibr" rid="bibr10-0961203313479421">10</xref></sup> Thus, the SLAM-SAP signaling pathway is important for the development of lupus traits and other autoimmune diseases. In this study, we analyzed five <italic>SH2D1A</italic> tag SNPs in Japanese female SLE patients and healthy female controls.</p>
</sec>
<sec id="sec2-0961203313479421" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203313479421" sec-type="subjects"><title>Patients and controls</title>
<p>Five hundred and six female patients with SLE (mean age ± standard deviation (SD), 44.6 ± 14.2 years) and 330 female healthy controls (mean age ± SD, 30.6 ± 8.8 years) were recruited at Sagamihara Hospital, University of Tsukuba, Juntendo University, Kitasato University, Komagome Hospital, the University of Tokyo, Himeji Medical Center, Morioka Hospital, Kyushu Medical Center and Yokohama Minami Kyosai Hospital. All patients and healthy individuals were native Japanese living in Japan. All patients with SLE fulfilled the American College of Rheumatology criteria for SLE.<sup><xref ref-type="bibr" rid="bibr11-0961203313479421">11</xref></sup> Since <italic>SH2D1A</italic> is located on the X chromosome, male and female individuals should be analyzed separately. However, due to the female predominance of SLE (female to male ratio 9:1), the sample size of male SLE patients was too small to be analyzed statistically. Therefore, male patients and controls were excluded from this study.<sup><xref ref-type="bibr" rid="bibr12-0961203313479421">12</xref></sup> This study was reviewed and approved by the research ethics committees of Sagamihara Hospital, Yokohama Minami Kyosai Hospital, Juntendo University, Kitasato University, Komagome Hospital, the University of Tokyo, Himeji Medical Center, Morioka Hospital, Kyushu Medical Center, University of Tsukuba and Tokyo Metropolitan Tama Medical Center. Written informed consent was obtained from all study participants. This study was conducted in accordance with the principles expressed in the Declaration of Helsinki.</p>
</sec>
<sec id="sec4-0961203313479421"><title>Genotyping</title>
<p>Five tag SNPs in <italic>SH2D1A</italic> region were selected based on the HapMap Phase II JPT (Japanese) data obtained from HapMap database (<ext-link ext-link-type="uri" xlink:href="http://hapmap.ncbi.nlm.nih.gov/">http://hapmap.ncbi.nlm.nih.gov/</ext-link>) with the criteria of minor allele frequency &gt;0..01 and an <italic>r<sup>2</sup></italic> threshold of 0.8. Genotyping of these five tag SNPs was carried out using the cycle sequencing method with the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, California, USA) or TaqMan genotyping assay on 7300 or 7500 Fast Real-Time polymerase chain reaction (PCR) System (Applied Biosystems), according to the manufacturer’s instructions. Thermal cycling conditions consisted of initial denaturation at 95°C for 10 min, followed by 50 cycles of 95°C for 15 s followed by 60°C for 1 min. rs6608190 [T/G] was genotyped using Custom TaqMan SNP Genotyping Assays. TaqMan SNP Genotyping Assays used in this study were as follows: Assay ID: C__29241299_10 (rs7357894 [A/G]), C__11614964_10 (rs2049995[T/G]), C__16174992_10 (rs2239481[C/T]), and C__30427796_10 (rs10284199[C/T]).</p>
</sec>
<sec id="sec5-0961203313479421"><title>Luciferase assay</title>
<p><italic>SH2D1A</italic> promoter region (−669 ∼ −1) was cloned between the KpnI and XhoI restriction sites of pGL3-Basic plasmid (Promega, Madison, Wisconsin, USA) upstream of <italic>luc</italic> gene in the forward direction. <italic>SH2D1A</italic> promoter was amplified from an individual homozygous for a haplotype of −631A (rs990545[A/G]), −494G (rs7357894[A/G]), −346T (rs12164382[C/T]) and −112G (rs79572799[G/T]) using the following primers: (KSAP5U-1(+): 5’-GGTACCGTGAGGTAGAA GGAAGAGGGAGAAG-3’, and XSAP5U-1(−): 5’-CTCGAGGGCCTGGTGGACTCTTGGGCAGG-3’). This vector was named pGL3-SH2D1Apro. Subsequently, a 5’ portion of the <italic>SH2D1A</italic> intron 2 sequence (NT_011786: 19482-20068, 587 bp) was cloned into the SalI site of pGL3-SH2D1Apro plasmid downstream of <italic>luc</italic> gene in the forward direction. The cloned 587 bp fragment of the <italic>SH2D1A</italic> intron 2 was amplified from individuals homozygous for haplotypes of 277del (rs5903659 [-/AAAG]), 317G (rs2049995[G/T]), and 392C (rs2206017[A/C]) or 277del, 317T, and 392C using the following primers: (SAPi2-1.1(+): 5’- GTATAGTTGTATTTATTTTTGCTTCTG-3’, and SAPi2-6.4(−): 5’- ATAAGGGAGGATTCTTAGGC-3’). The two vectors were named pGL3-SH2D1Apro-G and pGL3-SH2D1Apro-T based on the polymorphism in 317 (rs2049995, <xref ref-type="fig" rid="fig1-0961203313479421">Figure 1(B)</xref>). One hundred thousand Jurkat lymphoma cells (provided by Tohoku University, Institute of Development, Aging and Cancer, Cell Resource Center for Biomedical Research) were cotransfected with 20 ng pRL-TK Vector (Promega) and 180 ng of pGL3-SH2D1Apro, pGL3-SH2D1Apro-G or pGL3-SH2D1Apro-T vector using 0.6 µl of Transfectin™ (Bio-rad, Hercules, California, USA). Luciferase assay was performed after 48 h with Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer’s instruction. Data are shown as relative luciferase activity (Firefly/Renilla).
<fig id="fig1-0961203313479421" position="float"><label>Figure 1</label><caption><p>(A) Association study of five single nucleotide polymorphisms (SNPs) in <italic>SH2D1A</italic> gene with systemic lupus erythematosus (SLE). In the upper panel, <italic>p</italic> values under the dominant model for minor alleles are indicated. Association was tested by chi-square analysis using 2 × 2 contingency tables. In the lower panel, <italic>r</italic><sup>2</sup> values based on data from 330 female healthy individuals are shown. (B) The two constructs, pGL3-SH2D1Apro-G and pGL3-SH2D1Apro-T (containing a portion of intron 2 of SH2D1A gene with SNP rs2049995[T/G]), used in the luciferase assay. (C) Relative luciferase activity in Jurkat cells cotransfected with pGL3-SH2D1Apro, pGL3-SH2D1Apro-G or pGL3-SH2D1Apro-T vector and the internal control pRL-TK vector. Relative luciferase activity was normalized to Renilla luciferase activity of the internal control. The experiments were performed in triplicate and the mean value with standard deviation is shown. Mann–Whitney U test was performed in the comparison of luciferase assay results. The data shown are representative of three independent experiments.</p></caption><graphic xlink:href="10.1177_0961203313479421-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec6-0961203313479421"><title>Analysis of gene expression by real-time quantitative PCR</title>
<p>RNA was extracted from peripheral blood mononuclear cells (PBMCs) and complementary DNA (cDNA) was synthesized using Superscript III reverse transcriptase (Invitrogen, Carlsbad, California, USA). Gene expression was evaluated quantitatively by real-time PCR using a TaqMan Gene Expression Assay on 7500 Fast Real-Time PCR System. Thermal cycling conditions consisted of initial denaturation at 95°C for 20 s, followed by 40 cycles of 95°C for 3 s followed by 60°C for 30 s. The amount of specific cDNA was quantified using comparative Threshold Cycle (CT) method. The levels of cDNA among samples were normalized to the expression of <italic>GAPDH</italic>. The TaqMan Gene Expression Assay used in this study was Hs00158978_m1 for <italic>SH2D1A</italic>.</p>
</sec>
<sec id="sec7-0961203313479421"><title>Statistical analysis</title>
<p>Differences in allele and genotype frequencies between SLE patients and healthy controls were analyzed by chi-square test using 2 × 2 contingency tables. When one or more of the variables in the contingency tables were 5 or less, Fisher’s exact test was employed. Linkage disequilibrium (LD) was analyzed using Haploview v4.2 (Broad Institute, Cambridge, Massachusetts, USA). Pairwise <italic>r<sup>2</sup></italic> values were calculated based on the genotypes of 330 healthy controls. The Mann–Whitney U test was performed in the comparison of luciferase assay and real-time quantitative PCR results.</p>
</sec>
</sec>
<sec id="sec8-0961203313479421" sec-type="results"><title>Results</title>
<sec id="sec9-0961203313479421"><title>Associations of an SNP in SH2D1A with SLE</title>
<p>Five tag SNPs in <italic>SH2D1A</italic> gene were analyzed in Japanese female SLE patients and healthy female controls. No deviation from Hardy-Weinberg equilibrium was observed in the patients and the controls (<italic>p</italic> &gt; 0.05). There are three LD blocks including the five SNPs examined in this study (<xref ref-type="fig" rid="fig1-0961203313479421">Figure 1(A)</xref>) and the adjustment for multiple comparisons using the Bonferroni method defined statistical significance as <italic>p</italic> &lt; 0.0167 for this study. A significant association was observed for one SNP in intron 2, rs2049995 (<italic>p</italic> = 0.0110, odds ratio (OR) 1.97, 95% confidence interval (CI) 1.16–3.34, under the dominant model for the minor allele, <xref ref-type="table" rid="table1-0961203313479421">Table 1</xref>, <xref ref-type="fig" rid="fig1-0961203313479421">Figure 1(A)</xref>). Thus, an intronic SNP of <italic>SH2D1A</italic> is associated with SLE.
<table-wrap id="table1-0961203313479421" position="float"><label>Table 1</label><caption><p>Association of <italic>SH2D1A</italic> single nucleotide polymorphisms (SNPs) with systemic lupus erythematosus (SLE)</p></caption>
<graphic alternate-form-of="table1-0961203313479421" xlink:href="10.1177_0961203313479421-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="3">Allelic association</th>
<th colspan="3">Dominant model</th>
<th colspan="3">Recessive model</th>
</tr>
<tr><th>Genotype</th>
<th>Allele frequency</th>
<th><italic>p</italic></th>
<th>OR</th>
<th>(95% CI)</th>
<th><italic>p</italic></th>
<th>OR</th>
<th>(95% CI)</th>
<th><italic>p</italic></th>
<th>OR</th>
<th>(95% CI)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>rs7357894</td>
<td>A/A</td>
<td>G/A</td>
<td>G/G</td>
<td>A</td>
<td>G</td>
</tr>
<tr>
<td>SLE</td>
<td>30 (5.9)</td>
<td>167 (33.0)</td>
<td>309 (61.1)</td>
<td>227 (22.4)</td>
<td>785 (77.6)</td>
<td>0.8246</td>
<td>1.03</td>
<td>(0.81–1.30)</td>
<td>0.8966</td>
<td>1.02</td>
<td>(0.77–1.35)</td>
<td>0.7732</td>
<td>1.09</td>
<td>(0.60–1.99)</td>
</tr>
<tr>
<td>Controls</td>
<td>18 (5.5)</td>
<td>109 (33.0)</td>
<td>203 (61.5)</td>
<td>145 (22.0)</td>
<td>515 (78.0)</td>
</tr>
<tr>
<td>rs6608190</td>
<td>T/T</td>
<td>G/T</td>
<td>G/G</td>
<td>T</td>
<td>G</td>
</tr>
<tr>
<td>SLE</td>
<td>36 (7.1)</td>
<td>185 (36.6)</td>
<td>285 (56.3)</td>
<td>257 (25.4)</td>
<td>755 (74.6)</td>
<td>0.9108</td>
<td>1.01</td>
<td>(0.81–1.27)</td>
<td>0.8540</td>
<td>1.03</td>
<td>(0.78–1.36)</td>
<td>0.9310</td>
<td>0.98</td>
<td>(0.57–1.67)</td>
</tr>
<tr>
<td>Controls</td>
<td>24 (7.3)</td>
<td>118 (35.8)</td>
<td>188 (57.0)</td>
<td>166 (25.2)</td>
<td>494 (74.8)</td>
</tr>
<tr>
<td>rs2049995</td>
<td>T/T</td>
<td>G/T</td>
<td>G/G</td>
<td>T</td>
<td>G</td>
</tr>
<tr>
<td>SLE</td>
<td>0 (0.0)</td>
<td>57 (11.3)</td>
<td>449 (88.7)</td>
<td>57 (5.6)</td>
<td>955 (94.4)</td>
<td>0.0202</td>
<td>1.82</td>
<td>(1.09–3.03)</td>
<td>0.0110</td>
<td>1.97</td>
<td>(1.16–3.34)</td>
<td>0.3947 <sup><xref ref-type="table-fn" rid="table-fn3-0961203313479421">a</xref></sup></td>
<td>0.22</td>
<td>(0.01–5.34)</td>
</tr>
<tr>
<td>Controls</td>
<td>1 (0.3)</td>
<td>19 (5.8)</td>
<td>310 (93.9)</td>
<td>21 (3.2)</td>
<td>639 (96.8)</td>
</tr>
<tr>
<td>rs2239481</td>
<td>C/C</td>
<td>T/C</td>
<td>T/T</td>
<td>C</td>
<td>T</td>
</tr>
<tr>
<td>SLE</td>
<td>56 (11.1)</td>
<td>221 (43.7)</td>
<td>229 (45.3)</td>
<td>333 (32.9)</td>
<td>679 (67.1)</td>
<td>0.4300</td>
<td>1.09</td>
<td>(0.88–1.34)</td>
<td>0.5109</td>
<td>1.10</td>
<td>(0.83–1.45)</td>
<td>0.5280</td>
<td>1.16</td>
<td>(0.73–1.83)</td>
</tr>
<tr>
<td>Controls</td>
<td>32 (9.7)</td>
<td>141 (42.7)</td>
<td>157 (47.6)</td>
<td>205 (31.1)</td>
<td>455 (68.9)</td>
</tr>
<tr>
<td>rs10284199</td>
<td>C/C</td>
<td>T/C</td>
<td>T/T</td>
<td>C</td>
<td>T</td>
</tr>
<tr>
<td>SLE</td>
<td>56 (11.1)</td>
<td>227 (44.9)</td>
<td>223 (44.1)</td>
<td>339 (33.5)</td>
<td>673 (66.5)</td>
<td>0.6953</td>
<td>1.04</td>
<td>(0.85–1.28)</td>
<td>0.6941</td>
<td>1.06</td>
<td>(0.80–1.40)</td>
<td>0.8343</td>
<td>1.05</td>
<td>(0.67–1.64)</td>
</tr>
<tr>
<td>Controls</td>
<td>35 (10.6)</td>
<td>145 (43.9)</td>
<td>150 (45.5)</td>
<td>215 (32.6)</td>
<td>445 (67.4)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313479421"><p>CI: confidence interval; OR: odds ratio.</p></fn>
<fn id="table-fn2-0961203313479421"><p>Genotype and allele frequency are shown in parenthesis (%). Association was tested by chi-square analysis or Fisher's exact test using 2 × 2 contingency tables under the indicated models for minor alleles.</p></fn>
<fn id="table-fn3-0961203313479421"><label>a</label><p>Fisher's exact test was employed.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec10-0961203313479421"><title>Associations of rs2049995 with clinical subsets of SLE</title>
<p>We determined whether rs2049995 SNP was associated with clinical phenotypes (<xref ref-type="table" rid="table2-0961203313479421">Table 2</xref>). Association of this SNP with each phenotype of SLE was tested. A significant association was found for rs2049995 in the subset with the age of onset less than 20 years (<italic>p</italic> = 0.0067, OR 2.65, 95% CI 1.28–5.46, <xref ref-type="table" rid="table2-0961203313479421">Table 2</xref>), arthritis (<italic>p</italic> = 0.0028, OR 2.40, 95% CI 1.33–4.33), or lymphopenia (<italic>p</italic> = 0.0017, OR 2.47, 95% CI 1.39–4.42). The association of rs2049995 with anti-dsDNA (<italic>p</italic> = 0.0094, OR 2.05, 95% CI 1.18–3.54), anti-Ro/SSA (<italic>p</italic> = 0.0087, OR 2.35, 95% CI 1.22–4.51), or anti-La/SSB (<italic>p</italic> = 0.0118, OR 3.62, 95% CI 1.41–9.25) antibodies remained significant. Thus, rs2049995 SNP was associated with clinical subsets of SLE.
<table-wrap id="table2-0961203313479421" position="float"><label>Table 2</label><caption><p>Association of rs2049995 with clinical characteristics of systemic lupus erythematosus (SLE)</p></caption>
<graphic alternate-form-of="table2-0961203313479421" xlink:href="10.1177_0961203313479421-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="3">Allelic association</th>
<th colspan="3">Dominant model</th>
</tr>
<tr><th>Phenotype</th>
<th>Genotype</th>
<th>Allele frequency</th>
<th><italic>p</italic></th>
<th>OR</th>
<th>(95% CI)</th>
<th><italic>p</italic></th>
<th>OR</th>
<th>(95% CI)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>rs2049995</td>
<td>T/T</td>
<td>G/T</td>
<td>G/G</td>
<td>T</td>
<td>G</td>
</tr>
<tr>
<td>Controls</td>
<td>1 (0.3)</td>
<td>19 (5.8)</td>
<td>310 (93.9)</td>
<td>21 (3.2)</td>
<td>639 (96.8)</td>
</tr>
<tr>
<td>Age of onset &lt; 20</td>
<td>96 (20.0)</td>
<td>0 (0.0)</td>
<td>14 (14.6)</td>
<td>82 (85.4)</td>
<td>14 (7.3)</td>
<td>178 (92.7)</td>
<td>0.0116</td>
<td>2.39</td>
<td>(1.19–4.80)</td>
<td>0.0067</td>
<td>2.65</td>
<td>(1.28–5.46)</td>
</tr>
<tr>
<td>Malar rash (+)</td>
<td>173 (34.2)</td>
<td>0 (0.0)</td>
<td>19 (11.0)</td>
<td>154 (89.0)</td>
<td>19 (5.5)</td>
<td>327 (94.5)</td>
<td>0.0749</td>
<td>1.77</td>
<td>(0.94–3.34)</td>
<td>0.0499</td>
<td>1.91</td>
<td>(0.99–3.69)</td>
</tr>
<tr>
<td>Photosensitivity (+)</td>
<td>152 (30.0)</td>
<td>0 (0.0)</td>
<td>17 (11.2)</td>
<td>135 (88.8)</td>
<td>17 (5.6)</td>
<td>287 (94.4)</td>
<td>0.0739</td>
<td>1.80</td>
<td>(0.94–3.47)</td>
<td>0.0496</td>
<td>1.95</td>
<td>(0.99–3.84)</td>
</tr>
<tr>
<td>Arthritis (+)</td>
<td>231 (45.7)</td>
<td>0 (0.0)</td>
<td>31 (13.4)</td>
<td>200 (86.6)</td>
<td>31 (6.7)</td>
<td>431 (93.3)</td>
<td>0.0057</td>
<td>2.19</td>
<td>(1.24–3.86)</td>
<td>0.0028</td>
<td>2.40</td>
<td>(1.33–4.33)</td>
</tr>
<tr>
<td>Serositis (+)</td>
<td>76 (16.4)</td>
<td>0 (0.0)</td>
<td>10 (13.2)</td>
<td>66 (86.8)</td>
<td>10 (6.6)</td>
<td>142 (93.4)</td>
<td>0.0488</td>
<td>2.14</td>
<td>(0.99–4.65)</td>
<td>0.0330</td>
<td>2.35</td>
<td>(1.05–5.25)</td>
</tr>
<tr>
<td>Renal disorder (+)</td>
<td>238 (49.3)</td>
<td>0 (0.0)</td>
<td>22 (9.2)</td>
<td>216 (90.8)</td>
<td>22 (4.6)</td>
<td>454 (95.4)</td>
<td>0.2095</td>
<td>1.47</td>
<td>(0.80–2.71)</td>
<td>0.1526</td>
<td>1.58</td>
<td>(0.84–2.96)</td>
</tr>
<tr>
<td>Neurologic disorder (+)</td>
<td>102 (21.7)</td>
<td>0 (0.0)</td>
<td>11 (10.8)</td>
<td>91 (89.2)</td>
<td>11 (5.4)</td>
<td>193 (94.6)</td>
<td>0.1440</td>
<td>1.73</td>
<td>(0.82–3.66)</td>
<td>0.1062</td>
<td>1.87</td>
<td>(0.87–4.05)</td>
</tr>
<tr>
<td>Lymphopenia (+)</td>
<td>247 (48.8)</td>
<td>0 (0.0)</td>
<td>34 (13.8)</td>
<td>213 (86.2)</td>
<td>34 (6.9)</td>
<td>460 (93.1)</td>
<td>0.0035</td>
<td>2.25</td>
<td>(1.29–3.93)</td>
<td>0.0017</td>
<td>2.47</td>
<td>(1.39–4.42)</td>
</tr>
<tr>
<td>Anti–dsDNA Abs (+)</td>
<td>386 (82.1)</td>
<td>0 (0.0)</td>
<td>45 (11.7)</td>
<td>341 (88.3)</td>
<td>45 (5.8)</td>
<td>727 (94.2)</td>
<td>0.0172</td>
<td>1.88</td>
<td>(1.11–3.20)</td>
<td>0.0094</td>
<td>2.05</td>
<td>(1.18–3.54)</td>
</tr>
<tr>
<td>Anti–Sm Abs (+)</td>
<td>116 (25.2)</td>
<td>0 (0.0)</td>
<td>13 (11.2)</td>
<td>103 (88.8)</td>
<td>13 (5.6)</td>
<td>219 (94.4)</td>
<td>0.0975</td>
<td>1.81</td>
<td>(0.89–3.67)</td>
<td>0.0685</td>
<td>1.96</td>
<td>(0.94–4.07)</td>
</tr>
<tr>
<td>Anti–RNP Abs (+)</td>
<td>115 (22.7)</td>
<td>0 (0.0)</td>
<td>14 (12.2)</td>
<td>101 (87.8)</td>
<td>14 (6.1)</td>
<td>216 (93.9)</td>
<td>0.0509</td>
<td>1.97</td>
<td>(0.99–3.95)</td>
<td>0.0336</td>
<td>2.15</td>
<td>(1.05–4.41)</td>
</tr>
<tr>
<td>Anti–Ro/SSA Abs (+)</td>
<td>152 (30.0)</td>
<td>0 (0.0)</td>
<td>20 (13.2)</td>
<td>132 (86.8)</td>
<td>20 (6.6)</td>
<td>284 (93.4)</td>
<td>0.0152</td>
<td>2.14</td>
<td>(1.14–4.02)</td>
<td>0.0087</td>
<td>2.35</td>
<td>(1.22–4.51)</td>
</tr>
<tr>
<td>Anti–La/SSB Abs (+)</td>
<td>37 (7.3)</td>
<td>0 (0.0)</td>
<td>7 (18.9)</td>
<td>30 (81.1)</td>
<td>7 (9.5)</td>
<td>67 (90.5)</td>
<td>0.0166<sup><xref ref-type="table-fn" rid="table-fn6-0961203313479421">a</xref></sup></td>
<td>3.18</td>
<td>(1.30–7.75)</td>
<td>0.0118<sup><xref ref-type="table-fn" rid="table-fn6-0961203313479421">a</xref></sup></td>
<td>3.62</td>
<td>(1.41–9.25)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203313479421"><p>Abs: antibodies; CI: confidence interval; dsDNA: double-strand DNA; OR: odds ratio; RNP: ribonucleoprotein.</p></fn>
<fn id="table-fn5-0961203313479421"><p>Phenotype, genotype and allele frequency are shown in parenthesis (%). Association was tested by chi-square analysis or Fisher's exact test using 2 × 2 contingency tables under the indicated models for rs2049995T allele. Each SLE subset of clinical characteristics was compared with healthy controls.</p></fn>
<fn id="table-fn6-0961203313479421"><label>a</label><p>Fisher's exact test was employed.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec11-0961203313479421"><title>The effect of rs2049995 SNP on luciferase activity in Jurkat cells</title>
<p>The effect of rs2049995 SNP on the expression of <italic>SH2D1A</italic> was evaluated by luciferase assay. A 587 bp fragment of the 5’- portion of the <italic>SH2D1A</italic> intron 2 was cloned downstream of <italic>SH2D1A</italic> promoter and <italic>luc</italic> in the pGL3 vector (<xref ref-type="fig" rid="fig1-0961203313479421">Figure 1(B)</xref>) and the luciferase activity was analyzed in Jurkat cells transfected with the vectors. The vector containing susceptible allele [T] of rs2049995 showed a 1.9-fold increase in luciferase activity compared with that containing the resistant allele [G] (<italic>p</italic> = 0.0495, by Mann–Whitney U test, <xref ref-type="fig" rid="fig1-0961203313479421">Figure 1(C)</xref>). Two additional experiments were performed and resulted in the similar conclusion ([T]/[G] luciferase activity ratio = 1.9, 2.0; <italic>p</italic> = 0.0495, 0.0495, respectively). Thus, functional evaluation of rs2049995 showed increased reporter gene activity in the susceptible allele.</p>
</sec>
<sec id="sec12-0961203313479421"><title>The effect of rs2049995 SNP on SH2D1A gene expression in PBMCs</title>
<p>Association between rs2049995 SNP and <italic>SH2D1A</italic> mRNA levels was tested by use of the Mann–Whitney U test (Supplementary Figure 1). Difference of gene expression levels was not observed between two genotypes, G/G and G/T, in healthy controls or SLE patients because of the small sample number of individuals with G/T genotype or the immunosuppressive treatment for SLE.</p>
</sec>
</sec>
<sec id="sec13-0961203313479421" sec-type="discussion"><title>Discussion</title>
<p>Recent studies have shown that the SLAM-SAP signaling pathway contributes to the susceptibility to autoimmune diseases. Since SAP-deficient mice were protected from lupus traits,<sup><xref ref-type="bibr" rid="bibr3-0961203313479421">3</xref></sup> we postulated that <italic>SH2D1A</italic> polymorphisms might also contribute to SLE. To investigate the possibility, we analyzed five tag SNPs in <italic>SH2D1A</italic> and found associations of one SNP with SLE. To our knowledge, this is the first report of such associations with SLE. Our findings suggest a role for the SLAM-SAP signaling pathway in the pathogenesis of human autoimmune disease as well as autoimmune mouse models.</p>
<p>The association of the polymorphisms in <italic>SH2D1A</italic> and SLE was not reported even in genome wide association studies. It was suggested that the allele frequency of rs2049995 SNP is not high enough to be found in genome wide association study. In addition, the X chromosome was not analyzed in genome wide association studies.<sup><xref ref-type="bibr" rid="bibr13-0961203313479421">13</xref><xref ref-type="bibr" rid="bibr14-0961203313479421"/>–<xref ref-type="bibr" rid="bibr15-0961203313479421">15</xref></sup> We cannot rule out the possibility that other causative SNPs tagged by rs2049995 might exist. This possibility could be addressed by re-sequencing the entire <italic>SH2D1A</italic> region. As a result of the limited sample size of this study, the observed statistical association was modest. The associations of the SNP should be confirmed in future independent studies. Since the allele frequencies of rs2049995 SNP in other ethnic populations are higher than that in Japanese (0.034 in HapMap-JPT (Japanese), 0.108 in HapMap-CEU (European), 0.078 in HapMap-HCB (Chinese), and 0.292 in HapMap-YRI (Yoruba); data obtained from HapMap database), the role of rs2049995 SNP for SLE in other populations should be determined. In future studies, gel shift assays should be done on the SNP rs2049995 to identify the molecules involved in the regulation of <italic>SH2D1A</italic> expression.</p>
<p>Furthermore, the luciferase assay revealed the augmented reporter gene activity in the susceptible allele of rs2049995. Higher <italic>SH2D1A</italic> gene expression levels caused by the susceptible [T] allele of rs2049995 might effectively transduce signals in the SLAM-SAP signaling pathway of T cells, which would develop SLE. However, association of the intronic SNP with levels of <italic>SH2D1A</italic> mRNA was not actually confirmed. The mRNA levels should be examined in T or NK cells from a considerable number of healthy controls or SLE patients before starting immunosuppressive treatment, because SAP molecules were mainly expressed in T and NK cells.</p>
<p>This is the first identification of associations of an intronic SNP in <italic>SH2D1A</italic> with SLE. Our findings support the crucial role of SLAM-SAP signaling pathway in SLE pathogenesis.</p>
</sec>
</body>
<back>
<sec id="sec14-0961203313479421"><title>Funding</title>
<p>This work was supported by Grants-in-Aid for Scientific Research (<grant-sponsor>B, C</grant-sponsor>) (22390199, 22591090) from the Japan Society for the Promotion of Science, Health and Labour Science Research Grants from the Ministry of Health, Labour, and Welfare of Japan, Grants-in-Aid for Clinical Research from the National Hospital Organization, research grants from Daiwa Securities Health Foundation, Japan Research Foundation for Clinical Pharmacology, The Nakatomi Foundation, Takeda Science Foundation and from pharmaceutical companies: Abbott Japan Co., Ltd, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Ltd, Teijin Pharma Ltd. The funders had no role in study design, data collection and analysis, decision to publish or preparing the manuscript.</p>
</sec>
<sec id="sec15-0961203313479421"><title>Conflicts of interest</title>
<p>HF has the following conflicts and the following funders are supported in whole or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc.</p>
<p>ST was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Ltd and Teijin Pharma Ltd.</p>
<p>NT is supported by the Takeda Science Foundation which is supported by an endowment from Takeda Pharmaceutical Company.</p>
<p>The other authors declare no financial or commercial conflict of interest.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Mayumi Yokoyama (Sagamihara Hospital) for secretarial assistance. M Ono, N Tsuchiya, and S Tohma contributed equally to this work.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313479421"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Tohma</surname><given-names>S</given-names></name><name><surname>Kitazawa</surname><given-names>H</given-names></name><name><surname>Komori</surname><given-names>H</given-names></name><name><surname>Nose</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name></person-group>. <article-title>Role of SLAM-associated protein in the pathogenesis of autoimmune diseases and immunological disorders</article-title>. <source>Arch Immunol Ther Exp</source> <year>2010</year>; <volume>58</volume>: <fpage>37</fpage>–<lpage>44</lpage>.</citation></ref>
<ref id="bibr2-0961203313479421"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>. <article-title>Immune regulation by SLAM family receptors and SAP-related adaptors</article-title>. <source>Nat Rev Immunol</source> <year>2006</year>; <volume>6</volume>: <fpage>56</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr3-0961203313479421"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>H</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice</article-title>. <source>J Immunol</source> <year>2006</year>; <volume>176</volume>: <fpage>395</fpage>–<lpage>400</lpage>.</citation></ref>
<ref id="bibr4-0961203313479421"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><name><surname>Kakinuma</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn)</article-title>. <source>J Immunol</source> <year>1997</year>; <volume>159</volume>: <fpage>2532</fpage>–<lpage>2541</lpage>.</citation></ref>
<ref id="bibr5-0961203313479421"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Regulation of B cell tolerance by the lupus susceptibility gene Ly108</article-title>. <source>Science</source> <year>2006</year>; <volume>312</volume>: <fpage>1665</fpage>–<lpage>1669</lpage>.</citation></ref>
<ref id="bibr6-0961203313479421"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunninghame</surname><given-names>GDS</given-names></name><name><surname>Vyse</surname><given-names>TJ</given-names></name><name><surname>Fortin</surname><given-names>PR</given-names></name><etal/></person-group>. <article-title>Association of LY9 in UK and Canadian SLE families</article-title>. <source>Genes Immun</source> <year>2008</year>; <volume>9</volume>: <fpage>93</fpage>–<lpage>102</lpage>.</citation></ref>
<ref id="bibr7-0961203313479421"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Kochi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>1224</fpage>–<lpage>1229</lpage>.</citation></ref>
<ref id="bibr8-0961203313479421"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>M</given-names></name><name><surname>Ishiwata</surname><given-names>T</given-names></name><name><surname>Mitamura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Decreased expression of signaling lymphocytic-activation molecule-associated protein (SAP) transcripts in T cells from patients with rheumatoid arthritis</article-title>. <source>Int Immunol</source> <year>2001</year>; <volume>13</volume>: <fpage>559</fpage>–<lpage>565</lpage>.</citation></ref>
<ref id="bibr9-0961203313479421"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Takei</surname><given-names>M</given-names></name></person-group>. <article-title>Epstein-Barr virus etiology in rheumatoid synovitis</article-title>. <source>Autoimmun Rev</source> <year>2005</year>; <volume>4</volume>: <fpage>106</fpage>–<lpage>110</lpage>.</citation></ref>
<ref id="bibr10-0961203313479421"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isomaki</surname><given-names>P</given-names></name><name><surname>Aversa</surname><given-names>G</given-names></name><name><surname>Cocks</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium</article-title>. <source>J Immunol</source> <year>1997</year>; <volume>159</volume>: <fpage>2986</fpage>–<lpage>2993</lpage>.</citation></ref>
<ref id="bibr11-0961203313479421"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>M</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr12-0961203313479421"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>TLR7 single-nucleotide polymorphisms in the 3' untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: A case-control association study</article-title>. <source>Arthritis Res Ther</source> <year>2011</year>; <volume>13</volume>: <fpage>R41</fpage>–<lpage>R41</lpage>.</citation></ref>
<ref id="bibr13-0961203313479421"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JW</given-names></name><name><surname>Zheng</surname><given-names>HF</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus</article-title>. <source>Nat Genet</source> <year>2009</year>; <volume>41</volume>: <fpage>1234</fpage>–<lpage>1237</lpage>.</citation></ref>
<ref id="bibr14-0961203313479421"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Alarcon-Riquelme</surname><given-names>ME</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>204</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr15-0961203313479421"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Shimane</surname><given-names>K</given-names></name><name><surname>Kochi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese</article-title>. <source>PLoS Genet</source> <year>2012</year>; <volume>8</volume>: <fpage>e1002455</fpage>–<lpage>e1002455</lpage>.</citation></ref>
</ref-list>
</back>
</article>